Zyprexa

Automatic Data Processing (nyse: ADP - news - people ) and Network Appliance (nasdaq: NTAP - news - people ) will both host meetings with analysts tomorrow.

Goldman Sachs said last Friday ADP's analyst meeting should sport a positive tone since the company's overall business momentum remains strong, and management will likely outline a plan to improve shareholder value, which may include share buybacks or an acquisition strategy.

The firm reiterated an "outperform" rating on ADP, and said the company is "one of the most compelling ideas in IT services."Goldman Sachs said growth targets will be key for Network Appliance.

"With the stock trading at 39 times our calendar 2007 estimate and the shares up 24% year to date, we think a growth target of at least 30% is needed to keep the shares moving higher, with anything short of that likely leading to at least a stall if not a small pullback from current levels." The firm reiterated an "in-line" rating on NetApp shares.More On This Topic Companies: GS NTAP -% String xsl=(String) application.getAttribute(com.forbes.cms.Constants.XSL_REP_KEY)+"/story_body_html_trans.xsl"; final TransformerFactory tFactory = TransformerFactory.newInstance(); final Transformer transformer = tFactory.newTransformer(new StreamSource(xsl)); final ByteArrayOutputS...

Grasso has over 10 years of experience in biopharmaceutical R&D.

He co-founded Morphotek and has served as its VP of Research since its inception.

His team's efforts have led to the development of a pipeline of therapeutic antibodies in the area of cancer, inflammation and infectious disease.

He received his Ph.D.

in Pathology from the University of Catania, Italy and has held various R&D positions within the biopharmaceutical industry.

He has authored several papers in leading peer review journals and is an inventor with several key patents involving Morphotek's technologies and products."I am pleased to announce the addition of Bob to the team and the well deserved promotion of Luigi to Sr.

Vice President," commented Nicholas C.

Nicolaides, Ph.D., President and Chief Executive Officer of Morphotek.

"Bob brings a breadth of knowledge, energy and leadership to the company that will facilitate development of our technology and products for value creation.

His keen understanding of product development and pharmaceutical sales will undoubtedly help the company execute its goals in establishing alliances with appropriate partners who are capable of helping us advance our compounds from the clinic to the market as well as sign additional technology alliances.

Luigi's leadership in R&D has been essential for helping the company to optimize, validate and implement its technologies fr...